Pharmaceuticals Australia

Australia Gout Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Gout Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $42.2 Mn Placeholder estimate
Estimate 2025 $46.1 Mn 1.1% of the global market
Projected 2034 $102.7 Mn 122.6% Adds $56.5 Mn over 9 forecast years
CAGR 2025–2034 9.3% Faster than 46% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.13% of the global market.
  • In APAC, the largest is China at $292.5 Mn.
  • Fastest growing: India at 11% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$56.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Gout Treatment Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $42.2 Mn — —
2025 (base) $46.1 Mn +$3.9 Mn —
2026 (forecast) $50.4 Mn +$4.3 Mn +9.3%
2027 (forecast) $55.1 Mn +$4.7 Mn +19.5%
2028 (forecast) $60.2 Mn +$5.1 Mn +30.6%
2029 (forecast) $65.8 Mn +$5.6 Mn +42.7%
2030 (forecast) $71.9 Mn +$6.1 Mn +56%
2031 (forecast) $78.6 Mn +$6.7 Mn +70.5%
2032 (forecast) $85.9 Mn +$7.3 Mn +86.4%
2033 (forecast) $93.9 Mn +$8.0 Mn +103.7%
2034 (forecast) $102.7 Mn +$8.7 Mn +122.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.08 Bn
  2. North America $2.10 Bn
  3. US $1.41 Bn
  4. APAC $889.8 Mn
  5. Europe $770.6 Mn
  6. Canada $372.3 Mn
  7. China $292.5 Mn
  8. Japan $233.3 Mn
  9. Middle East $186.7 Mn
  10. Latin America $163.1 Mn
  11. Germany $141.7 Mn
  12. France $119.0 Mn
  13. UK $117.2 Mn
  14. Brazil $119.5 Mn
  15. Italy $102.5 Mn
  16. Ecuador $86.4 Mn
  17. Spain $80.8 Mn
  18. India $83.8 Mn
  19. Africa $69.3 Mn
  20. Saudi Arabia $62.4 Mn
  21. Mexico $55.0 Mn
  22. Australia (this report) $46.1 Mn
  23. Russia $44.0 Mn
  24. New Zealand $43.8 Mn
  25. South Africa $26.4 Mn
  26. UAE $20.8 Mn
  27. Egypt $10.6 Mn
  28. Philippines $9.1 Mn
  29. Hong Kong $7.3 Mn
  30. Malaysia $7.3 Mn
  31. Singapore $5.6 Mn
  32. Thailand $5.2 Mn
  33. Kenya $3.0 Mn

Report snapshot

Australia Gout Treatment Market Analysis at a glance
Market size, 2025$46.1 Mn placeholder estimate
Forecast, 2034$102.7 Mn placeholder estimate
Growth (CAGR), 2025–20349.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, type and end user (see all)
Key playersHorizon Therapeutics (Amgen), Takeda Pharmaceutical Company Ltd, Novartis AG, Teva Pharmaceutical, Shanton Pharma (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Gout Treatment Market Analysis Executive Summary

Gout treatments lower uric acid and control painful flares caused by crystals in the joints.

Key segments of the gout Treatment market include drug class (Xanthine Oxidase Inhibitors, Uricosurics and Colchicine) and type (Acute Gout and Chronic Gout).

Bar chart: Australia Gout Treatment market size, 2024–2034, placeholder estimates. $42.2 Mn in 2024, $46.1 Mn in 2025 and $102.7 Mn in 2034, 9.3% CAGR.
Australia Gout Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Gout Treatment Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the gout Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the gout Treatment market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the gout Treatment market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Gout Treatment Market in Australia

The gout Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Gout Treatment Market in Australia

Gout Treatment in Australia: rules and payment

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gout Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Gout Treatment right now, from free public sources.

Latest research 135 papers since 2021 (worldwide)

  1. Telemedicine in Rheumatology in the United States: A Scoping Review of Modalities, Outcomes, and Costs in Support of a Hybrid Model of Care. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2026
  2. Molecular modelling study on Piper betle phytocompounds to discover the potential active moiety responsible for xanthine oxidase inhibition in avian gout. British poultry science, 2026
  3. Colchicine-related effects on gene and protein expression in gout. Current opinion in rheumatology, 2026
  4. Modulatory effects of methyl gallate on the inflammatory response in gout arthritis via P2X7 receptor. Anais da Academia Brasileira de Ciencias, 2026
  5. A self-management app in a digital treat-to-target gout-care approach: the ReMonit Gout feasibility study. Scandinavian journal of rheumatology, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Gout Treatment in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Gout Treatment market in Australia?
Placeholder estimate: about $46.1 Mn in 2025, rising to about $102.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Gout Treatment market in Australia growing?
Placeholder estimate: about 9.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Gout Treatment market report cover?
The report splits the market by drug class (Xanthine Oxidase Inhibitors, Uricosurics, Colchicine, NSAIDs and more), type (Acute Gout, Chronic Gout) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Gout Treatment market?
Key players include Horizon Therapeutics (Amgen), Takeda Pharmaceutical Company Ltd, Novartis AG, Teva Pharmaceutical and Shanton Pharma.
What is driving the Gout Treatment market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the gout Treatment market.
Who regulates Gout Treatment in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How much research is published on Gout Treatment?
PubMed lists 135 papers on Gout Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Gout Treatment in Australia? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Cannabis-Based Medicines: Science and RegulationThe FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Australia

See all
Same topic, other categories

Related on pain

See the topic